Fisher Asset Management LLC Acquires 33,222 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)

Fisher Asset Management LLC increased its holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) by 48.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 101,791 shares of the technology company’s stock after buying an additional 33,222 shares during the period. Fisher Asset Management LLC owned about 0.10% of Cogent Biosciences worth $599,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. AJOVista LLC bought a new position in Cogent Biosciences in the fourth quarter worth approximately $45,000. China Universal Asset Management Co. Ltd. raised its stake in Cogent Biosciences by 355.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,961 shares of the technology company’s stock worth $59,000 after buying an additional 7,772 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Cogent Biosciences in the fourth quarter worth approximately $70,000. NEOS Investment Management LLC bought a new position in Cogent Biosciences in the fourth quarter worth approximately $76,000. Finally, E Fund Management Co. Ltd. bought a new position in Cogent Biosciences in the fourth quarter worth approximately $91,000.

Cogent Biosciences Price Performance

Shares of COGT opened at $8.79 on Monday. The firm has a market capitalization of $840.41 million, a PE ratio of -3.54 and a beta of 1.60. Cogent Biosciences, Inc. has a 1-year low of $3.67 and a 1-year high of $13.36. The company’s fifty day moving average price is $7.70 and its 200-day moving average price is $6.70.

Cogent Biosciences (NASDAQ:COGT) last announced its quarterly earnings data on Tuesday, May 7th. The technology company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). As a group, research analysts anticipate that Cogent Biosciences, Inc. will post -2.19 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on COGT shares. Robert W. Baird reaffirmed a “neutral” rating and set a $8.00 price target (down from $14.00) on shares of Cogent Biosciences in a research report on Monday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $18.00 price target on shares of Cogent Biosciences in a research report on Monday, June 17th. Wedbush reaffirmed a “neutral” rating and set a $10.00 price target on shares of Cogent Biosciences in a research report on Friday, May 24th. JPMorgan Chase & Co. upped their price target on Cogent Biosciences from $18.00 to $20.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. Finally, Citigroup upped their price target on Cogent Biosciences from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Monday, February 26th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $14.67.

Cogent Biosciences Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.